Surfactant Protein A (SP-A) is a Prognostic Molecular Biomarker in Acute Respiratory Distress Syndrome

Мороз, В. В.; Голубев, М. А.; Kuzovlev, N F; Писарев, М; Половников, Г.; Шабанов, К; Голубев, А. М

doi:10.15360/1813-9779-2013-3-5

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Увеличение уровня SP-A и SP-D в сыворотке крови отмечается при тяжелой внебольничной пневмонии по сравнению с не тяжелой формой и отсутствием бронхолегочных заболеваний[37]. Повышенный уровень SP-A и SP-D также является чувствительным и специфичным прогностическим биомаркером развития ОРДС и летального исхода при ОРДС[38][39][40][41]. Прямое взаимодействие SP-A и SP-D с рядом вирусов приводит к нейтрализации вируса и усилению фагоцитоза.…”

unclassified

Biomarkers of Air-Blood Barrier Damage In COVID-19

Khadzhieva

Gracheva²,

Ершов³

et al. 2021

Obŝaâ reanimatologiâ

Self Cite

View full text Add to dashboard Cite

The search for sensitive and specific markers enabling timely identification of patients with a life-threatening novel coronavirus infection (COVID-19) is important for a successful treatment.The aim of the study was to examine the association of molecular biomarkers of air-blood barrier damage, surfactant proteins SP-A and SP-D and Club cell protein CC16, with the outcome of patients with COVID-19.Materials and methods. A cohort of 109 patients diagnosed with COVID-19 was retrospectively divided into two groups. Group 1 comprised survivor patients discharged from the ICU (n=90). Group 2 included the patients who did not survive (n=19). Association of disease outcome and SP-A, SP-D, and CC16 levels in blood serum, clinical, and laboratory data were examined taking into account the day of illness at the time of biomaterial collection.Results. The non-survivors had higher SP-A (from days 1 to 10 of symptoms onset) and lower CC16 (from days 11 to 20 of symptoms onset) levels vs survivors discharged from ICU. No significant differences in SP-D levels between the groups were found.Conclusion. According to the study results, the surfactant protein SP-A and Clara cell protein CC16 are associated with increased COVID-19 mortality.

show abstract

unclassified

Biomarkers of Air-Blood Barrier Damage In COVID-19

Khadzhieva

Gracheva²,

Ершов³

et al. 2021

Obŝaâ reanimatologiâ

Self Cite

View full text Add to dashboard Cite

show abstract

Association of SP-A and SP-D Surfactant Proteins with the Severity of CommunityAcquired Pneumonia

Сергеевна

Николаев

Ragino

et al. 2020

Neotložnaâ med. pomoŝʹ

View full text Add to dashboard Cite

Relevance. In current clinical practice, there is a need for research to find new diagnostic tests for the purpose of determining the patients with the highest risk of death from pneumonia. Surfactant proteins SP-A and SP-D play a key role in the pathogenesis of the response to microbial invasion of lung tissue, which participate in a cascade of reactions of both innate and adaptive immunity, and therefore proteins SP-A and SP-D may be considered as markers of the severity of community-acquired pneumonia (CAP).Aim of study. To evaluate the associations of surfactant proteins SP-A and SP-D in blood plasma with the severity of CAP.Material and methods. The study included 247 patients admitted to the therapeutic department. The group of patients with CAP (n=188) was divided into groups of severe (n=103) and non-severe (n=85) pneumonia. The comparison group (n=59) consisted of patients without acute and chronic diseases of the bronchi and lungs. The mean age (years, Me, 25th; 75th percentile) of patients was 55 (47; 68), 55 (47; 70), and 61 (37; 63) years, respectively. All patients underwent clinical, functional, diagnostic and laboratory studies (including determination of the content of SP-A and SP-D proteins by enzyme immunoassay).Results. In the group of patients with severe pneumonia unlike mild pneumonia, and group of comparison higher levels of proteins SP-A and SP-D were observed. Correlation analysis described below revealed statistically significant connection: protein SP-D — direct relation with leukocyte levels (r=0.320, p<0.0001), erythrocyte sedimentation rate (r=0.331, p<0.0001), inverse relation with blood oxygen saturation (r=-0.407, p<0.0001), for SP-A protein — direct relation with body temperature (r=0.355, p<0.0001), erythrocyte sedimentation rate (r=0.369, p<0.0001) in the blood C-reactive protein (r=0.446, p<0.0001), SP-D (r=0.357, p<0.0001), and also relation with the duration of clinical symptoms (r=0.528, p<0.0001) and blood oxygen saturation (r=-0.401, p<0.0001). When conducting ROCanalysis for the surfactant protein SP-A, the area under the ROC- curve was 0.70, the optimal sensitivity for severe pneumonia was 68%, the specificity was 69% at the SP-A level in blood plasma equal to 42.9 ng/ml. When performing ROC analysis for the surfactant protein SP-D, the area under the ROC curve was 0.64 for severe pneumonia, the optimal sensitivity was 62%, and the specificity was 62% at the SP-D content in blood plasma equal to 319.2 ng/ml.Conclusion. According to the results of this study, the SP-A and SP-D proteins are associated with clinical and laboratory signs that reflect the severity of CAP. Thus, SP-A and SP-D are new laboratory markers of CAP severity.

show abstract

Surfactant Protein A (SP-A) is a Prognostic Molecular Biomarker in Acute Respiratory Distress Syndrome

Cited by 2 publications

References 3 publications

Biomarkers of Air-Blood Barrier Damage In COVID-19

Biomarkers of Air-Blood Barrier Damage In COVID-19

Association of SP-A and SP-D Surfactant Proteins with the Severity of CommunityAcquired Pneumonia

Contact Info

Product

Resources

About